474490.KQ Yuanta 16 SPECIAL PURPOSE ACQUISITION COMPANY Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
11:01
Jan 09
Jan 09
Orum can mirror ABL Bio's re-rating.
Orum Therapeutics had existing cash and strengthened its balance sheet with a large rights offering, giving it sufficient funding for clinical trials. The speaker picks it as a promising stock that could show a similar re-rating to ABL Bio this year.
MED
About 474490.KQ Investor Commentary
Across the available history and selected sources, Buzzberg tracks 474490.KQ (Yuanta 16 SPECIAL PURPOSE ACQUISITION COMPANY) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Kim Dong-yeop.